REPORT HIGHLIGHT
Antibiotic Resistance Market size was valued at USD 8,005.7 million in 2022, expanding at a CAGR of 6.1% from 2023 to 2030.
Antibiotic resistance emerges when bacteria adapt to the usage of these medications. It develops in bacteria instead of people or animals. These bacteria can infect humans and animals, and their infections are more difficult to treat than infections caused by non-resistant bacteria. Antibiotic resistance is accelerated by antibiotic abuse and overuse, as well as inadequate infection prevention and control. At all levels of society, steps can be made to decrease the impact and spread of resistance. Antibiotic resistance is a global issue and requires cooperation between nations, industries, and organizations. Investing in the development of new antibiotics, as well as alternative therapies like bacteriophages and antimicrobial peptides. For example, Methicillin-Resistant Staphylococcus Aureus (MRSA's) emergence and spread show the quick rate at which germs can adapt to drugs, as well as the continual problem that healthcare personnel face in treating bacterial illnesses. It emphasizes the critical need for effective antibiotic usage, improved infection control procedures, and the discovery of novel antibiotics.
Antibiotic Resistance Market - Market Dynamics:
- Increasing the prevalence of bacterial infection to increase market growth
- The increasing prevalence of bacterial illnesses resistant to conventional antibiotics may increase demand for novel remedies, driving market growth. As antibiotic resistance spreads, the need for new antibiotics becomes more pressing. This could lead to increased investment in R&D by pharmaceutical corporations. Global comprehensive estimates of the burden of bacterial infections have been published. In 2019, 7.7 million deaths around the world were found to be linked to bacterial infections. That equals 1 in 8 of all global deaths. The integration of AI and machine learning in drug research provides a growth opportunity to accelerate the creation of novel antibiotics. However, Antibiotic resistance is not widely recognized by the general population and even by healthcare providers. This can lead to incorrect prescribing and abuse.
Antibiotic Resistance Market - Key Insights:
- As per the analysis shared by our research analyst, the global Antibiotic Resistance market is estimated to grow annually at a CAGR of around 6.1% over the forecast period (2023-2030)
- Based on Disease type segmentation, Urinary Tract Infections was predicted to show maximum market share in the year 2022
- Based on Pathogen Type segmentation, Acinetobacter Baumannii was the leading type in 2022
- Based on Drug class segmentation, Oxazolidinones were the leading type in 2022
- Based on End-User segmentation, Hospitals was the leading type in 2022
- On the basis of region, North America was the leading revenue generator in 2022
Antibiotic Resistance Market- Segmentation Analysis:
- The Global Antibiotic Resistance Market is segmented on the basis of Disease type, Pathogen Type, Drug class, End-User, and Region.
- The market is divided into four categories based on Disease type: Urinary Tract Infections, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, and Others. Urinary Tract Infections dominate the market growth. UTIs are one of the most common bacterial diseases that affect humans, particularly women. UTIs are often treated with antibiotics. However, with the increasing prevalence of antibiotic resistance, managing and treating UTIs is becoming more difficult.
- The market is divided into four categories based on Pathogen Type: Acinetobacter Baumannii, Pseudomonas Aeruginosa, Staphylococcus Aureus, Streptococcus pneumonia, and Others. Acinetobacter Baumannii dominates the market growth. A. baumannii has an inherent propensity to rapidly acquire resistance mechanisms, making it one of the most troublesome infections in hospital settings, particularly in intensive care units (ICUs).
- The market is divided into three categories based on Drug class: Oxazolidinones, Lipoglycopeptides, Tetracyclines, and Others. The Oxazolidinones sector dominates the market and is likely to maintain its dominance during the forecast period. Oxazolidinones are antibiotics that are used to treat bacterial infections, particularly those caused by Gram-positive pathogens. Linezolid is the most well-known oxazolidinone. They are especially significant since they have been shown to be effective against multi-drug resistance pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
- The market is divided into three categories based on End-User: Hospitals, Homecare, Specialty Clinics, and Others. The hospital sector dominates the market. Hospitals are essential to the development of antibiotic resistance. They are both a breeding ground for resistant bacteria and a main battleground for treating people sick with these superbugs. The implications for hospitals in the face of developing antibiotic resistance are complex, with considerable ramifications for the healthcare market.
Antibiotic Resistance Market - Geographical Insights:
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the growth of the market, due to the increasing prevalence of infectious diseases and rising healthcare expenditure. North America, especially the United States, has had outbreaks of many infectious diseases, some of which are antibiotic-resistant. MRSA (Methicillin-resistant Staphylococcus aureus), for example, has become a major concern in many U.S. hospitals and healthcare settings. The United States spends more on healthcare per capita than any other country in the world. According to the American Medical Association, a significant amount of the revenue is spent on research, drug development, and diagnostics. Health spending in the U.S. increased by 2.7% in 2021 to USD 4.3 trillion or USD 12,914 per capita. This growth rate is substantially lower than in 2020 (10.3% percent). Europe and Asia Pacific are projected to demand for Bispecific Resistance Market, due to the growing demand for effective antibiotic therapies.
Antibiotic Resistance Market- Competitive Landscape:
Antibiotic resistance has emerged as a major global concern. As bacteria evolve and become resistant to existing medicines, infections become more challenging to treat, leading to longer illnesses, more hospitalizations, and a rise in mortality. The manufacturers have been active in antibiotic research, however owing to economic pressures, some large pharmaceutical corporations have reduced or discontinued their antibiotic research projects. Pfizer, Merck, GlaxoSmithKline, and Roche represent some of the companies involved in the pharmaceutical industry. A comprehensive competitive study must consider pharmaceutical businesses, diagnostic companies, research institutes, and alternative treatment modalities. For instance, On May 2021, Basilea Pharmaceutical Ltd. (SIX: BSLN) announced today that it has been awarded a grant of up to USD 2.7 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global partnership dedicated to supporting the early development of antibacterial products to diagnose, prevent and treat drug-resistant infections.
Recent Developments:
November 18, 2020, Merck, known as MSD outside the United States and Canada, recently, announced the launch of a new website for the global Study for Monitoring Antimicrobial Resistance Trends (SMART). SMART, which was initiated in 2002, is one of the world's largest and longest-running antimicrobial resistance (AMR) surveillance studies including more than 200 sites across more than 60 countries.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTIBIOTIC RESISTANCE MARKET KEY PLAYERS
- Achaogen Inc
- Nabriva Therapeutics plc
- BioVersys AG
- Johnson & Johnson Services, Inc.
- Destiny Pharma plc
- Armata Pharmaceuticals, Inc.
- West Way Health
- The Medicines Company
- Merck & Co., Inc.
- Pfizer Inc.
- CARB-X
- Melinta Therapeutics LLC
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- GSK plc.
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd
GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DISEASE TYPE
- Urinary Tract Infection
- Intra-Abdominal Infections
- Blood Stream Infections
- Clostridium Difficile Infections
- Others
GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY PATHOGEN TYPE
- Acinetobacter Baumannii
- Pseudomonas Aeruginosa
- Staphylococcus Aureus
- Streptococcus pneumoniae
- Others
GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY DRUG CLASS
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Others
GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY END-USER
- Hospitals
- Homecare
- Specialty Clinics
- Others
GLOBAL ANTIBIOTIC RESISTANCE MARKET, BY REGION
- North America
- The U.S.
- Canada
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA